CORRECTION

Correction to: Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation

Ou Yamaguchi[1] · Kyoichi Kaira[1] · Atsuto Mouri[1] · Ayako Shiono[1] · Kosuke Hashimoto[1] · Yu Miura[1] · Fuyumi Nishihara[1] · Yoshitake Murayama[1] · Kunihiko Kobayashi[1] · Hiroshi Kagamu[1]

Correction to:
Cancer Chemotherapy and Pharmacology
(2019) 83:817–825
https://doi.org/10.1007/s00280-019-03790-w

In the original publication of the article, the authors found few errors and the corrections are given below:

1. **Abstract**

    Results: "By multivariate analysis, smoking, performance status (PS), and time on treatment of 1st TKI with more than 10 months were confirmed to be independent prognostic factors predicting a worse progression-free survival" has been changed to "By multivariate analysis, smoking, performance status (PS) and time on treatment of 1st TKI with more than 10 months were confirmed to be independent prognostic factors predicting a better progression-free survival (PFS)".

2. **Results**

    Patient demographics
    "*EGFR* mutation analysis revealed 35 patients with deletion of exon19, 19 patients with L858R (exon 21), and 2 patients with other mutations" has been changed to "*EGFR* mutation analysis revealed 35 patients with deletion of exon

19, 19 patients with L858R (exon 21), and 8 patients with other mutations".

3. In the online publication of the article, the values in the Table 2 mentioned under the column smoking ($N=62$) and also value under the Gender, the column under the PFS (HR), has incorrectly published. The corrected Table 2 has been given below:

4. Under the figure 1, the text in the figure legends has been incorrectly published. The corrected text is given below:

    "A statistically significant difference in the PFS ($p=0.22$) (C) and OS ($p=0.44$) (D) was not observed in the patients between more than and less than 6 months".

5. The captions for the Figure 2 has been changed from

    a) TTF of prior EGFR-TKI: > 10 months ≤ 10 months to Time on treatment of prior EGFR-TKI: > 10 months ≤10 months
    b) TTF of prior EGFR-TKI: > 10 months ≤10 months to Time on treatment of prior EGFR-TKI: > 10 months ≤10 months.

    The corrected Fig. 2 has been given below:

6. In the online published article, the Figure legends under the figure 2 has been changed from

    "Forest plot of 5-year PFS (**a**) and OS (**b**) rates according to time on treatment using cut-off values of 10 months in each variables" to
    "Forest plot of PFS (**a**) and OS (**b**) rates according to time on treatment using cut-off values of 10 months in each variables".

✉ Kyoichi Kaira
    kkaira1970@yahoo.co.jp

1   Department of Respiratory Medicine Comprehensive Cancer Center, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka-City, Saitama 350-1298, Japan

Table 2 Univariate survival analysis according to different variables

Variables	N = 62	PFS				OS			
		Median (days)	HR	95% CI	*p* value	Median (days)	HR	95% CI	*p* value
Age									
≤ 69/> 69 years	35/27	174/194	1.12	0.64–1.92	0.15	572/485	1.42	0.76–2.65	0.26
Gender									
Male/female	25/37	144/209	1.36	0.91–3.03	0.09	532/587	0.96	0.51–1.81	0.92
Smoking									
Yes/no	28/34	213/94	0.44	0.24–0.82	**< 0.01**	572/551	0.91	0.49–1.68	0.75
ECOG PS									
0–1/2–3	42/20	227/73	0.43	0.23–0.83	**0.01**	778/153	0.32	0.15–0.67	**< 0.01**
BSA									
≤ 1.5/> 1.5	43/19	168/227	0.77	0.43–1.39	0.39	501/904	0.74	0.38–1.45	0.39
EGFR mutation status									
Del 19/L858R	35/19	174/168	0.99	0.54–1.81	0.98	754/505	0.59	0.28–1.24	0.12
Time on treatment of prior EGFR-TKI (months)									
≤ 6/> 6	7/55	60/195	0.19	0.05–0.66	**< 0.01**	145/587	0.21	0.05–0.78	**0.02**
≤ 8/> 8	11/51	94/195	0.33	0.13–0.84	**0.02**	389/587	0.32	0.11–0.98	**0.04**
≤ 10/> 10	16/46	73/222	0.41	0.19–0.87	**0.02**	389/587	0.36	0.14–0.87	**0.02**
≤ 12/> 12	17/45	85/209	0.43	0.21–0.91	**0.02**	389/587	0.42	0.18–0.96	**0.04**
≤ 14/> 14	22/40	73/238	0.36	0.18–0.71	**< 0.01**	389/667	0.34	0.16–0.72	**< 0.01**
≤ 20/> 20	32/30	109/256	0.45	0.25–0.81	**< 0.01**	532/754	0.63	0.34–1.17	0.14
Time from prior EGFR-TKI to afatinib (months)									
≤ 4/> 4	39/23	168/209	0.63	0.36–1.11	0.11	505/704	0.68	0.36–1.26	0.22
≤ 6/> 6	42/20	194/191	0.71	0.40–1.24	0.22	532/704	0.78	0.41–1.46	0.44
≤ 12/> 12	52/10	194/134	0.60	0.29–1.21	0.15	551/704	0.82	0.37–1.76	0.61
Cytotoxic agent between prior EGFR-TKI and afatinib									
Yes/no	31/31	194/164	0.73	0.42–1.27	0.26	532/704	0.53	0.28–1.00	0.05
Initial dosage of afatinib									
40/20 or 30 mg	46/16	171/238	1.22	0.67–2.21	0.52	551/667	1.21	0.59–2.43	0.61
Disease stage at the initiation of prior EGFR-TKI									
IV/recurrence after surgical resection	43/19	174/194	1.46	0.83–2.03	0.19	551/587	1.42	0.76–2.67	0.29
Treatment line of afatinib									
≤ 3/> 3 lines	33/29	213/168	0.66	0.38–1.13	0.11	572/551	1.02	0.55–1.86	0.95
Numbers of initial EGFR-TKI before afatinib									
½	36/26	209/156	0.59	0.34–1.03	0.05	667/437	0.59	0.32–1.09	0.08

Bold indicates statistically significant difference

ECOG eastern cooperative oncology group, *PS* performance status, *PFS* progression free survival, *OS* overall survival, *HR* hazard ratio, *95% CI* 95% confidence interval, *EGFR* epidermal growth factor receptor, *TKI* tyrosine kinase inhibitor, *BSA* body surface area

		HR	95% CI	p-value
Age	≦69	0.50	0.21-1.21	0.12
	>69	0.21	0.04-1.04	0.05
Gender	male	0.38	0.11-1.27	0.11
	female	0.43	0.15-1.17	0.09
BSA	≦1.5	0.41	0.15-1.12	0.08
	>1.5	0.34	0.09-1.20	0.09
ECOG PS	0-1	0.72	0.26-1.93	0.51
	2-3	0.24	0.07-0.79	0.02
Smoking	Yes	0.15	0.05-0.54	<0.01
	No	0.70	0.25-1.93	0.49
EGFR mutation	Del 19	0.05	0.01-0.21	<0.01
	L858R	1.04	0.33-3.26	0.94
Treatment line	≦3	0.49	0.19-1.26	0.13
	>3	0.08	0.02-0.44	<0.01
TKI off duration	≦6M	0.27	0.11-0.71	<0.01
	>6M	0.79	0.20-3.12	0.74
Chemotherapy	Yes	0.28	0.06-1.31	0.11
	No	0.50	0.21-1.22	0.12
Afatinib dose	40mg	0.60	0.26-1.37	0.22
	30 /20mg	0.06	0.01-0.43	<0.01

Time on treatment of prior EGFR-TKI : >10 months ≦10 months

Fig. 2 Series 62 Model 4666 extrapolations

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.